On November 10, 2025, the U.S. Department of Health and Human Services and the Food and Drug Administration announced that the FDA would begin removing the boxed warning — the most serious and prominent warning the agency uses — from menopausal hormone therapy products. The agency asked manufacturers to remove blanket label statements about the risk of cardiovascular disease, breast cancer, and probable dementia.

The decision followed a comprehensive review of the scientific literature, an FDA expert panel held in July 2025, and a public comment period. Dozens of drug companies were asked to submit proposed labeling changes. Because those updates roll out product by product, the change is still working its way through the market.

What a “boxed warning” is — and where this one came from

A boxed warning (often called a “black box” warning) is the strongest caution the FDA can place on a prescription drug. Much of the warning on systemic hormone therapy traces back to the Women’s Health Initiative (WHI), a large study whose early-2000s findings led many women and clinicians to abandon hormone therapy over fears about heart disease and breast cancer.

In the years since, researchers and medical societies have argued that those population-level findings were widely over-generalized — applied to younger women near the start of menopause for whom the balance of benefits and risks looks quite different, and even to low-dose vaginal products that are barely absorbed into the bloodstream. Removing the boxed warning is intended to bring the labeling closer to that more nuanced, current understanding.

What the change does — and does not — mean

It is important to read this news carefully. Removing a warning from a label changes the labeling, not your personal risk. Hormone therapy still has real benefits and real risks, and how they balance depends on your age, how long it has been since your last period, your personal and family medical history, and which formulation you use.

A few points clinicians emphasize:

  • Timing matters. For many healthy women who start hormone therapy before age 60 or within about 10 years of menopause — the so-called “timing hypothesis” — the benefit-to-risk balance is generally more favorable than it is for women who start much later.
  • Not all hormone therapy is the same. Low-dose vaginal estrogen used for genitourinary symptoms delivers very little hormone to the rest of the body, and its risk profile differs from systemic pills and patches.
  • It is not a prompt to start or stop treatment. This announcement is not medical advice to begin hormone therapy — or to stop it if you are doing well on it.

How experts reacted

The Menopause Society, a leading professional body for menopause clinicians, publicly welcomed clearer labeling, noting that the long-standing boxed warning had discouraged many women who could safely benefit from treatment — particularly those needing vaginal estrogen. At the same time, some researchers have urged caution against over-correcting, stressing that individualized risk assessment and shared decision-making with a clinician remain essential. If you want a plain-language look at where the evidence actually stands, see our guide to common HRT myths.

What it means for you

If you are already using hormone therapy and it is working, this news does not require any action — keep the follow-up plan you have with your clinician. If you have been avoiding hormone therapy because of the warnings, or you are weighing it for hot flashes, night sweats, or vaginal symptoms, this is a reasonable moment to have an informed conversation about your individual benefits and risks. Bring your medical history and a list of your symptoms, and ask specifically about the formulation and dose that fit your situation.

This article reports on a regulatory change and is not a substitute for personal medical advice. Talk with a qualified clinician before starting, stopping, or changing any treatment.